drugset / Trial / NCT06029309
Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma
Phase 1/2
Recruiting
27 enrolled
Alvaro Alencar, MD
BeiGene · collabIncyte Corporation · collabMorphoSys AG · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The main purpose of this study to find the ideal dose for the combination treatment of Zanubrutinib and Tafasitamab in patients with mantle cell lymphoma. Another purpose is to assess how well the combination treatment works in patients with the study disease.
Timeline
- Start
- 2024-05-03
- Primary completion
- 2028-05-01
- Completion
- 2032-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tafasitamab | Monoclonal antibody | 12 mg/kg | Intravenous |
| Subject | Zanubrutinib | Small molecule | 240 mg | Oral |
| Subject | Zanubrutinib | Small molecule | 320 mg | Oral |